Discovering New Anti-Infective Agents from Lysobacter

从溶杆菌中发现新的抗感染剂

• 批准号: 8485539
• 负责人: LIANGCHENG DU
• 金额: $ 20.2万
• 依托单位: UNIVERSITY OF NEBRASKA LINCOLN
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-06-15 至 2016-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8485539
• 关键词: Actinobacteria class; Address; Agriculture; Amides; Amino Acids; Anabolism; Anti-Infective Agents; Antibiotics; Antifungal Agents; Antifungal Antibiotics; Attention; Bacteria; Biochemical; Biocontrols; Biological Factors; Chemical Structure; Chemicals; Chemistry; Clinical Research; Communicable Diseases; Complex; Daptomycin; Development; Disease Outbreaks; Drug resistance; Employee Strikes; Engineering; Enzymes; Family; Fatty Acids; Gene Cluster; Gene Expression; Genes; Genome; Goals; Gram-Positive Bacteria; Grant; Health; Human; Hybrids; Infection; Lead; Life; Link; Logic; Lysobacter; Membrane; Molecular; Morbidity - disease rate; Multi-Drug Resistance; Nature; Oomycetes; Ornithine; Oxidation-Reduction; Peptides; Pharmacologic Substance; Phase; Production; Productivity; Proteins; Proteobacteria; Reaction; Regulation; Research; Resistance; Resort; Signal Transduction; Soil; Source; Streptomyces; Structure; System; Testing; Time; Vancomycin; Water; base; design; dihydromaltophilin; drug development; extracellular; fungus; genome sequencing; gliding bacteria; hydroxy fatty acid; methicillin resistant Staphylococcus aureus; mortality; novel; pathogen; peptide synthase; polyketide synthase; product development; public health relevance; receptor; research study; scaffold; small molecule

DESCRIPTION (provided by applicant): Multi-drug resistance has become an increasingly important cause of mortality and morbidity in humans. It is a pressing and continual need to discover new anti-infective agents. Bioactive natural products are a major source of anti-infective drugs. Traditionally, soil bacteria, especially the Gram-positive Streptomyces, have been the primary source for bioactive natural products. However, many ubiquitous inhabitants of soil and water, such as the Gram-negative gliding bacteria Lysobacter, remain largely unexplored, even though they are prolific producers of natural products. This proposal describes a research plan to discover and evaluate new anti-infectives with novel structures and potent activities from the new sources. The focus is on deciphering their biosynthetic and regulatory mechanisms. Specifically, two groups of bioactive natural products, HSAF and WAP-8294A, will be investigated. HSAF (dihydromaltophilin) is a polycyclic tetramate macrolactam (PTM) and represents a novel type of antifungal compounds with new chemistry and new mode of action. To develop HSAF as a new type of antifungal antibiotics, it is important to understand the biosynthetic mechanism for the novel chemical structure. The HSAF biosynthetic gene cluster contains only a single-module polyketide synthase-nonribosomal peptide synthetase (PKS/NRPS), flanked by a cascade of six redox enzymes, although HSAF biosynthesis apparently requires two separate hexaketide chains that are linked together by one amino acid (ornithine) via two amide bonds. This system represents an unprecedented iterative PKS/NRPS hybrid. The goal here is to illustrate the reactions catalyzed by the "redox enzymes-modulated iterative PKS/NRPS", which lead to the distinct PTM structure. WAP-8294A are a complex of at least 20 cyclic lipodepsipeptides with a potent activity against Methicillin-Resistant Staphylococcus aureus (MRSA, ED5014 times more active than vancomycin, a "last resort" antibiotic). Due to a very low yield, only the major component of the complex, WAP-8294A2, is in clinical studies (by aRigen Pharmaceuticals). Although the compounds were first isolated nearly 15 years ago and one of them is in clinical studies, their biosynthetic genes were just identified in 2011. The goal here is to determine the molecular mechanisms for WAP biosynthesis and regulation, particularly the mechanism for fatty acid incorporation that leads to structural diversity. The understanding of the biosynthetic and regulatory mechanisms for HSAF and WAP-8294A is an essential step toward rational biosynthetic engineering, productivity improvement and structure-activity optimization of these two groups of very promising bioactive natural products. In addition, because Lysobacter are prolific natural product producers that have not been exploited, this research will open a new direction to discovering new anti-infective drugs.

描述（由申请人提供）：多药耐药性已成为人类死亡和发病的一个日益重要的原因。发现新的抗感染药物是一个迫切而持续的需求。具有生物活性的天然产物是抗感染药物的主要来源。传统上，土壤细菌，特别是革兰氏阳性链霉菌，一直是生物活性天然产物的主要来源。然而，许多无处不在的土壤和水的居民，如革兰氏阴性滑动细菌溶杆菌，仍然在很大程度上未被探索，即使他们是多产的天然产物生产者。本提案描述了从新来源发现和评价具有新结构和有效活性的新抗感染药物的研究计划。重点是破译它们的生物合成和调节机制。具体而言，两组生物活性天然产物，HSAF和WAP-8294 A，将进行研究。HSAF（dihydromaltophilin）是一种多环四酸酯大环内酰胺（PTM），是一类具有新化学结构和新作用方式的新型抗真菌化合物。HSAF作为一种新型的抗真菌抗生素，其生物合成机制的研究对于开发该类抗生素具有重要意义。HSAF生物合成基因簇仅包含一个单模块聚酮合酶-非核糖体肽合成酶（PKS/NRPS），两侧是六种氧化还原酶的级联，尽管HSAF生物合成显然需要两个独立的六酮链，这些链通过一个氨基酸连接在一起（通过两个酰胺键）。该系统代表了前所未有的迭代PKS/NRPS混合。这里的目标是说明由“氧化还原酶调节的迭代PKS/NRPS”催化的反应，这导致了不同的PTM结构。WAP-8294 A是一种至少20个环状脂缩肽的复合物，对耐甲氧西林金黄色葡萄球菌（MRSA，ED 5014倍于万古霉素，一种“最后的手段”抗生素）具有强效活性。由于产率非常低，只有复合物的主要成分WAP-8294 A2处于临床研究中（由aRigen Pharmaceuticals进行）。尽管这些化合物在近15年前首次分离出来，其中一种正在临床研究中，但它们的生物合成基因在2011年才被发现。这里的目标是确定WAP生物合成和调节的分子机制，特别是导致结构多样性的脂肪酸掺入机制。对HSAF和WAP-8294 A的生物合成和调控机制的理解是这两组非常有前途的生物活性天然产物的合理生物合成工程，生产力提高和结构-活性优化的重要一步。此外，由于溶杆菌是尚未开发的多产天然产物生产者，这项研究将为发现新的抗感染药物开辟新的方向。